In a significant move within the pharmaceutical sector, Shanghai Pharmaceuticals Holding Co. has agreed to purchase the Chinese pharmaceutical distribution business of US-based Cardinal Health for $557 million. The deal, announced amid looming drug distribution reforms in China, marks a major shift for Cardinal Health as it reevaluates its growth strategy in the region. Details […]
Sanofi and Principia Biopharma have announced a significant partnership to develop and commercialize PRN2246, a promising oral drug candidate for multiple sclerosis (MS) and other central nervous system (CNS) diseases. The deal, which could be worth up to $805 million, positions PRN2246, a Bruton’s tyrosine kinase (BTK) inhibitor, at the forefront of MS treatment development. […]
Valeant Pharmaceuticals International has announced a significant transaction involving the sale of Sprout Pharmaceuticals back to its original owners. This strategic divestiture includes a deal where Valeant will receive a 6% royalty on global sales of Sprout’s female libido drug, Addyi (flibanserin), for 18 months following the closure of the sale. Background of the Acquisition […]
In a significant shift within the pharmaceutical industry, Pfizer Inc. has announced its decision to exit the Hisun-Pfizer Pharmaceuticals joint venture by divesting its 49% stake to Sapphire I (HK) Holdings. The deal, for which the terms were not disclosed, marks the end of Pfizer’s involvement in the Chinese generic drugs market through this joint […]